Epiprocare: To Take Care For Life

Epigenetics will certainly present a revolution in understanding people's concept of their health.

In order to understand the formation of living beings, Aristoteles (384-322 A.C.) developed the model of Epigenesis (ἐπιγένησις). From amorphous substances the specific structures of a living being were formed. The environment has a central role here.

How this occurs and what it means to us becomes more evident day by day through the countless new scientific discoveries in biology and medicine.

Men will increasingly come to the conclusion that they are not victims of old age, defenseless from their rigid mechanisms of genetic donations. Instead, epigenetics teaches us that human genes are able to respond to the action of external factors, for example, adapting its regulation, which can also mean an adaptation of the organism. Therefore, external factors include food, climate, stress, UV rays, bacteria, toxins, viruses, chemicals, but also other substances found in nature, such as Medication.

Added external factors and the genetics of each, our organism forms an entity with the environment that determines its health, quality of life and life time.

EPIPROCARE proposes the task of bringing this important knowledge of epigenetics as soon as possible to the application for the benefit of human beings.

Fortunately, humans are, in principle, able to consciously determine the influence of these external factors on their organisms and genes. Nevertheless, we must pay attention to what the EPIGENETICS will teach us, because it explores the connections between environmental influences and gene regulation.

EPIPROCARE proposes to bring this important knowledge of epigenetics as quickly as possible for application to the benefit of the human being.

Just as EPIGENETICS works between external environmental influences and gene regulation, E P I P R O C A R E will act between the findings of scientific research and its clinical application, acting directly on the quality of human life.

In this way, humans should be able to test and improve your (there) health, and even prevent and combat diseases.

For this purpose, EPIPROCARE was founded by internationally renowned biologists and physicians from top universities, with over 20 years of experience in the areas of Epigenetics and Clinical Urology.

The first practical application of EPIPROCARE is the scientific determination of the biological age of a person to show ways to have a positive impact on their aging process and in their quality of life in elderly patients.

Other scientific discoveries and determinations are also foreseen in the diagnosis and prognosis of urological neoplasms, such as prostate and bladder cancer first and then to be extended to almost all cancer entities, e.g. breast, lung, hepatocellular and gastric carcinoma, chronic lymphocytic leukemia (CLL) and others.


Has developed and presents a new method of reliably measuring epigenetic changes, scientifically tested, proven, published and patented, that for the first time accurately detects epigenetic changes in clinical specimens, which are subjected to genetic alterations, e.g. as it is the case in elderly individuals and cancer samples.

The method is IDLN-MSP: Idiolocal normalization of real-time methylation-specific PCR (Polymerase Chain Reaction) (Santourlidis et al. 2016) and constitutes the central pillar of epiprocare´s platform technology to provide a superior level of epigenetic diagnosis and prognosis for many cancer entities, e.g. bladder, prostate, breast, lung, hepatocellular and gastric carcinoma, chronic lymphocytic leukemia (CLL) and others. This technology allows the successful transfer in the personalized medicine to support and help any individual patient since for the first time, based on EPIPROCARE´S unique technology, it is possible to comparatively measure tumor samples and samples of aged individuals with disturbed genetics.

Responsible Directors

Prof. Dr.
Marcelo Bendhack
Chief of Executive Officer

Marcelo Bendhack, Master and Doctor in Urology by the Federal University of Paraná (UFPR/1999). Pos-Doc in Uro-Oncology by the University Düsseldorf, Germany (2001). Specialist by the Brazilian Society of Urology (SBU) and President of the Latin American Society of Uro-Oncology (UROLA). Member of the Board – World Federation of Uro-Oncology (WUOF), medical member of the Nossa Senhora das Graças Hospital (Curitiba/PR) and Santa Catarina Hospital (São Paulo/SP).

Prof. Dr.
Simeon Santourlidis
Scientific Management
Research and Development

Dr. rer. nat. degree (magna cum laude). Habilitation and Venia Legendi for Molecular Medicine at the Medical Faculty of the Heinrich-Heine University Düsseldorf. Promotion to "außerplanmäßiger Professor" (associate professor) for Molecular Medicine at the Medical Faculty of the Heinrich-Heine University Düsseldorf.

In Memoriam

Prof. Dr.
Rolf Ackermann

Prof. Dr. Rolf Ackermann died on February 11th, 2015. His clinical and scientific training included education in Germany and the United States. He was “instrumental in making German urology visible beyond the borders of the German-speaking world in the post–World War II era.”